Overview

• US biopharmaceutical companies have conducted hundreds of clinical trials in China over the past decade.
• Trials involved collaboration with Chinese military-run hospitals, including those in Xinjiang.
• Lawmakers cite risks of intellectual property theft and data trustworthiness issues.
• Concerns include potential forced participation of Uyghurs in Xinjiang trials.
• FDA has been asked to review and respond to these issues by October 1.